Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (CPSE:NOVO B) continues to draw attention after recent share price moves, with the stock showing mixed returns across different time frames and a sizeable footprint in global diabetes, obesity, and rare disease markets.
See our latest analysis for Novo Nordisk.
With the share price at DKK249.0, Novo Nordisk’s recent pattern combines a 5.82% 1 month share price return with a 37.23% 3 month decline and a 36.29% 1 year total shareholder return decline. This suggests momentum has faded after earlier gains.
If you are looking beyond a single healthcare name, it could be a good moment to scan for other opportunities in the sector using our 126 healthcare AI stocks
With Novo Nordisk trading at DKK249.0, a reported 67.56% intrinsic discount and a 23.56% discount to analyst targets hint at potential value. The question is whether this represents a genuine opening or a market that is already pricing in future growth.
Tokyo’s widely followed narrative pegs Novo Nordisk’s fair value at DKK851.04, far above the last close at DKK249.0, implying a large valuation gap.
With high barriers to entry, a booming market for obesity treatment, and a pipeline that keeps expanding, Novo Nordisk’s future looks remarkably secure. The company also benefits from deep expertise, a strong brand, and a massive manufacturing network that rivals would struggle to replicate.
It is worth examining what sits behind that punchy fair value, discount rate, and growth path Tokyo is using. The assumptions on revenue, margins, and future earnings multiples are anything but casual.
Result: Fair Value of DKK851.04 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this upbeat view could be challenged by tighter regulatory scrutiny around obesity treatments, as well as tougher pricing or reimbursement decisions in key markets like the US.
Find out about the key risks to this Novo Nordisk narrative.
With such a split between risks and rewards, it makes sense to move quickly, review the numbers yourself, and weigh both sides using the 4 key rewards and 5 important warning signs.
If you are weighing your next move, do not stop at a single stock; broaden your watchlist with fresh ideas that fit different goals and risk levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com